AMAROX LIMITED

• ⚠

  Material uncertainty over going concern

  We draw attention to Note 2 in the financial statements which indicates that the group incurred a net loss of £3,388,859 during the year ended 31 March 2025 and, as at that date, had net current liabilities of £672,003. As stated in Note 2, the group is reliant on the financial support of its immediate parent company. There is, however, no contractual certainty that this financial support will continue, as the support confirmations providided are not legally binding. These events and conditions, along with other matters as set forth in Note 2, indicate that a material uncertainty exists that may cast significant doubt on the group's and company's ability to continue as a going concern.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Smartax Limited

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to Note 2 in the financial statements which indicates that the group incurred a net loss of £3,388,859 during the year ended 31 March 2025 and, as at that date, had net current liabilities of £672,003. As stated in Note 2, the group is reliant on the financial support of its immediate parent company. There is, however, no contractual certainty that this financial support will continue, as the support confirmations providided are not legally binding. These events and conditions, along with other matters as set forth in Note 2, indicate that a material uncertainty exists that may cast significant doubt on the group's and company's ability to continue as a going concern.”

Group structure

1. AMAROX LIMITED · parent
   1. Tarbis Farma S.L 99.99% · Spain · selling and distribution of pharmaceutical products
   2. Amarox Pharma B.V 100% · Netherlands · selling and distribution of pharmaceutical products
   3. Amarox Pharma France 100% · France · selling and distribution of pharmaceutical products

Significant events

• “Following the year end, in May 2025, the group incorporated a new subsidiary, Amarox Pharma Sp. z o.o, in Poland.”
• “In June 2025 the group disposed of its 100% shareholding in Amarox Pharma B.V to its immediate parent company. As the transaction occurred after the reporting date, it has not been reflected in these financial statements. The transaction resulted in a gain of approximately £126,000, which will be recognised in the next financial year.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -32.5%

  £137,797 → £93,018

  lowest in 3 filed years

• Net assets

  -1.8%

  £11,854,613 → £11,640,720

  first positive since 2020

• Employees

  —

  Not reported

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers